Ron Finley, RPh of UCSF’s Memory and Aging Center discusses the drugs and treatments currently in the FDA’s pipeline for the treatment of Alzheimer’s Disease.
Video Rating: 0 / 5
Drugs in Development for the Treatment of Alzheimer’s Disease
Alzheimer's disease
Just another Blog Post HQ Sites site
@UCSFMemoryandAging Hehe. I’m not concerned about my old age. I’m saying we need a systemic change. We need to start providing genuine care, and stop forcing people to take useless medicines with mostly side effects.
@winstono75 I agree that each person’s treatment needs to be individually determined by the physician, patient and caregiver/person with durable power of attorney. Since you have strong feelings about any care that you might receive, I would advise you, and others like you, to create a legal care plan and share these desires with the people that may need to make decisions for you in the event that you are not able to do so.
@UCSFMemoryandAging I just don’t agree with how the weighing of benefits against risks is being done. Any person choosing for themselves would want to have as clear a mind as possible. These drugs are usually imposed from without because other people don’t want to deal with what they consider difficult behavior. Altering other people’s brain chemistry so it is easier for you to deal with them doesn’t seem very benign to me. And what it comes down to is that drugs generate financial income…
@winstono75 Low doses of atypical antipsychotics such as quetiapine, olanzepine or risperidone can be used for agitation, aggression or psychotic behavior, but the potential benefit must be weighed against the potential risks. Typical antipsychotics usually should be avoided in people with motor symptoms. Medications for behavioral symptoms should be initiated at a low dose and then subsequently titrated slowly based on the patient’s response and the presence of adverse effects.
Let’s stop giving old people anti-psychotics. The pharmaceutical industry will still survive.